Alpha Cognition (OTC:ACOGF) Stock Price Down 4.9% – Here’s Why

Alpha Cognition Inc. (OTC:ACOGF) shares traded down 4.9% during mid-day trading on Wednesday . The stock traded as low as C$0.36 and last traded at C$0.37. 186,822 shares were traded during mid-day trading, an increase of 144% from the average session volume of 76,488 shares. The stock had previously closed at C$0.39.

Analysts Set New Price Targets

Separately, Raymond James upgraded shares of Alpha Cognition from a “hold” rating to a “moderate buy” rating in a research note on Monday, July 15th.

Alpha Cognition Stock Down 4.9 %

The stock has a market capitalization of C$43.86 million, a PE ratio of -2.65 and a beta of 2.81. The firm’s fifty day moving average is C$0.42 and its 200-day moving average is C$0.50.

Alpha Cognition (OTC:ACOGF) last issued its earnings results on Monday, August 12th. The company reported C($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of C($0.04) by C$0.03. On average, analysts expect that Alpha Cognition Inc. will post -0.19 EPS for the current year.

About Alpha Cognition

Alpha Cognition Inc, a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.